IN BRIEF: Oxford BioDynamics loss widens; says well placed for 2022

Oxford BioDynamics PLC - biotechnology firm focused on discovery and development of epigenetic ...

Alliance News 25 January, 2022 | 6:06PM
Email Form Facebook Twitter LinkedIn RSS

Oxford BioDynamics PLC - biotechnology firm focused on discovery and development of epigenetic biomarkers - Revenue for financial year ended September 30 falls to GBP341,000 from GBP456,000 the year before, with pretax loss widening to GBP7.6 million from GBP4.9 million. Staff costs rise to GBP3.8 million from GBP2.7 million, and depreciation & amortisation charge more than doubles to GBP1.1 million from GBP467,000. Says it achieved progress in year, with launch of first products and expansion of its UK and US infrastructure. Business is "well positioned for commercial success" in 2022. "I firmly believe that in 2022 we will begin to see rewards for the hard work that has been done and I look forward to updating shareholders as the year progresses," says Chief Executive Jon Burrows.

Current stock price: 27.15 pence, down 8.0% on Tuesday

12-month change: down 66%

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Oxford BioDynamics PLC 8.99 GBX -3.23 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures